Changes

'''Gardasil''', the recently-available HPV vaccine, protects against types 6, 11, 16 and 18 of the human papillomavirus (HPV), which are sexually transmitted diseases.  These strains of HPV have been associated with 70% of cervical cancer cases and may also play a role in the development of other types of cancer <ref>[http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref>. In June 2006, the U.S. Food and Drug Administration approved the first HPV vaccine based on observance of elevated [[antibody]] levels in a few thousand patients who had received the vaccine (including perhaps only a few hundred or less young girls).

'''Gardasil''', the recently-available HPV vaccine, protects against types 6, 11, 16 and 18 of the human papillomavirus (HPV), which are sexually transmitted diseases.  These strains of HPV have been associated with 70% of cervical cancer cases and may also play a role in the development of other types of cancer <ref>[http://www.cancer.gov/cancertopics/factsheet/Risk/HPV]</ref>. In June 2006, the U.S. Food and Drug Administration approved the first HPV vaccine based on observance of elevated [[antibody]] levels in a few thousand patients who had received the vaccine (including perhaps only a few hundred or less young girls).

The HPV vaccine does not protect against other sexually transmitted diseases (e.g., chlamydia, herpes, hepatitis, trichomoniasis, gonorrhea, syphilis, [[HIV]], [[AIDS]], etc.).  The vaccine is not recommended for use in pregnant women or girls.[http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf]

The HPV vaccine does not protect against any other sexually transmitted diseases.  The vaccine is not recommended for use in pregnant women or girls.[http://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf]

The long-term consequences of the HPV vaccine are not known and there have not been any long-term studies.  Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine.  Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine.

The long-term consequences of the HPV vaccine are not known and there have not been any long-term studies.  Children in the 9-year-old age group have been monitored for 18 months, and there have been no studies of possible longer-term risks of the vaccine.  Between July 2006 and January 2007, there were 82 reports of adverse events filed with the Vaccine Adverse Event Reporting System ([[VAERS]]) following the receipt of the vaccine.